UNION is a clinical-stage, diversified pharmaceutical company focused on identifying, developing and commercializing treatments for immunology and infectious diseases. Our current portfolio is comprised of two medicinal compound classes with established modes of action that hold significant potential to address unmet medical needs. UNION is based in Greater Copenhagen, Denmark.
UNION works with molecules that have broadly applicable modes of action and demonstrated safety within immunology and infectious diseases.
UNION currently works with two lead molecules with broad applicability across therapeutic areas:
- Orismilast is a next-generation PDE4 inhibitor with demonstrated broad anti-inflammatory properties selected based on an attractive therapeutic window (i.e., the combination of improved efficacy and tolerability)
- Niclosamide is a broad spectrum anti-infective that modulates electrochemical gradients across biological membranes. The potent activity across a range of pathogenic viruses and bacteria supports wide applicability across respiratory infections and beyond
It is a part of UNION’s strategy to in-license molecules for further development. UNION expects to continue to source additional new molecules with well characterized modes of action and safety profiles that can be developed broadly within respiratory infections and immunology.